has developed a new biomaterial with high potential in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a promising approach to bone ...

Researchers discover that bone marrow cancer cells diversify drastically when exiting the bone marrow, which also affects the ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients ...

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

The team tackled a critical challenge in treating multiple myeloma -- a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center (DKFZ), the Berlin Institute of Health ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

More information: Raphael Lutz et al, Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma, Science Immunology (2025). DOI: 10.1126/sciimmunol ...

The team tackled a critical challenge in treating multiple myeloma—a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.